US20100004285A1 - POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID - Google Patents
POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID Download PDFInfo
- Publication number
- US20100004285A1 US20100004285A1 US12/561,148 US56114809A US2010004285A1 US 20100004285 A1 US20100004285 A1 US 20100004285A1 US 56114809 A US56114809 A US 56114809A US 2010004285 A1 US2010004285 A1 US 2010004285A1
- Authority
- US
- United States
- Prior art keywords
- crystalline form
- bilastine
- liquid
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N CCOCCN1C2=CC=CC=C2N=C1C1CCN(CCC2=CC=C(C(C)(C)C(=O)O)C=C2)CC1 Chemical compound CCOCCN1C2=CC=CC=C2N=C1C1CCN(CCC2=CC=C(C(C)(C)C(=O)O)C=C2)CC1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C)(C(O)=O)c1ccc(CCN(CC2)CCC2c2nc3ccccc3[n]2*)cc1 Chemical compound CC(C)(C(O)=O)c1ccc(CCN(CC2)CCC2c2nc3ccccc3[n]2*)cc1 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention refers to a new crystalline form of 4-[2-[4-[1-(2-ethoxyethyl)-1H benzimidazole-2-yl]-1-piperidinyl]ethyl]- ⁇ -dimethyl-benzeneacetic acid (herein referred to as “bilastine”) of formula (I).
- crystalline form 1 From hereon referred to as crystalline form 1, to procedures used to prepare it, to pharmaceutical formulae that contain crystalline form 1 and to the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals, such as man.
- bilastine can exist in three different crystalline polymorphic forms, each with different physical properties.
- the invention refers to crystalline form 1 of bilastine, characterised by X-ray crystallographic analysis, with approximate crystal parameters as follows:
- the crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide tablet that has the following characteristic absorption bands, expressed in reciprocal centimetres:
- FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
- FIG. 1 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 1. (Vertical axis: Transmission (%); Horizontal axis: Wavenumber (cm ⁇ 1 )).
- FIG. 2 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 2. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm ⁇ 1 )).
- FIG. 3 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 3. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm ⁇ 1 )).
- bilastine can exist in three clearly different polymorphic forms called crystalline form 1, crystalline form 2 and crystalline form 3.
- Crystalline form 3 is not very stable and is difficult to obtain in the pure form. Both crystalline form 2 and crystalline form 3 are converted into crystalline form 1 by the procedures of this invention.
- Crystalline form 1 of bilastine has a melting point of 200.3° C.
- Crystalline form 2 has a melting point of 205.2° C.
- Crystalline form 3 has a melting point of 197.0° C.
- the crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
- FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
- the crystalline form 2 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
- FIG. 2 represents the infrared spectrum of the crystalline form 2 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
- the crystalline form 3 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
- FIG. 3 represents the infrared spectrum of the crystalline 3 of the bilastine in a potassium bromide tablet recorded in Perkin Elmer Spectrum One FTIR spectrophotometer.
- Crystalline form 1 of bilastine is a very stable polymorph at room temperature and is, therefore, very useful as an active ingredient of a pharmaceutical preparation. Crystalline form 1 is also stable when stored at temperatures above room temperature.
- the crystalline form 1 of bilastine is characterised by the following data of its X-ray crystallographic analysis as a monocrystal, with crystal parameters of approximately the following values:
- FIG. 1 shows the complete infrared spectrum of crystalline form 1 of bilastine in potassium bromide, recorded with Perkin Elmer Spectrum One spectrophotometer.
- compositions of this invention can contain, as well as an effective quantity of crystalline form 1 of bilastine as an active ingredient as an antiallergic or antihistaminic agent, several pharmaceutically acceptable excipients.
- the solid pharmaceutical preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
- a solid excipient can be one of several substances that act as diluents, aromatising agents, agglutinants or disintegrating agents and an encapsulation material.
- the powders and tablets preferentially contain from approximately 5 to approximately 20 per cent of the active ingredient.
- Appropriate solid excipients are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, waxes with low melting point, cocoa butter and similar products.
- preparation includes the formulation of the active ingredient with an excipient for encapsulation to produce a capsule in which the active ingredient (with or without other excipients) is surrounded with the excipient by an encapsulation material. Tablets, powders, cachets and capsules can be used as suitable forms for oral administration.
- the active ingredient can also be incorporated into a chewing gum that can contain sweeteners, flavorings and colorings as appropriate.
- a compound with a low melting point such as a mixture of fatty acid glycerides or cocoa butter
- the active ingredient is mixed well and homogeneously dispersed in the mixture with agitation.
- the homogeneous melted mixture is placed in the appropriate moulds and left to cool until it solidifies.
- Liquid preparations comprise suspensions that can be made by mixing the finely divided active ingredient in water with suspension agents.
- topical preparations are considered for nasal, ophthalmic and dermal use.
- Appropriate formulae for nasal administration can correspond to solutions or suspensions.
- Ophthalmic formulae can be suspensions and ointments.
- Dermal preparations can be suspensions, ointments and creams.
- Ointments usually contain lipophylic excipients such as mineral oil or vaseline.
- a compound for transdermic use, consisting of a therapeutically effective amount of active ingredient incorporated into an excipient that corresponds to a liquid, a gel, a solid matrix or an adhesive patch sensitive to pressure, to be released via a transdermic administration system.
- the effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for topical administration varies between 0.1 and 5% of the total weight of the pharmaceutical compound.
- the preferred amount ranges from 0.1 to 2% of the total weight of the pharmaceutical compound.
- the effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for oral administration varies from 1 to 50 mg/day, with preferably an amount corresponding to approximately 2 to 20 mg/day in a single or fractionated doses.
- Crystalline form 1 of bilastine has antihistaminic properties that have been demonstrated in experimental pharmacological models, such as preventing histamine-induced lethality in the guinea-pig and antagonism against cutaneous capillary permeability induced by histamine in the rat.
Abstract
Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-αα-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.
Description
- This application is a Continuation of application Ser. No. 10/511,822 having a filing date under 35 U.S.C. § 371(c) of Mar. 23, 2005, which is presently pending, and which, in turn, is a U.S. National Stage filing under 35 U.S.C. § 371 of International Patent Application No. PCT/ES02/00194 filed Apr. 19, 2002, the priority of which is claimed herein.
- The invention refers to a new crystalline form of 4-[2-[4-[1-(2-ethoxyethyl)-1H benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid (herein referred to as “bilastine”) of formula (I).
- From hereon referred to as
crystalline form 1, to procedures used to prepare it, to pharmaceutical formulae that containcrystalline form 1 and to the use ofcrystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals, such as man. - U.S. Pat. No. 5,877,187 confers the rights to bilastine, a preparation with antihistaminic properties without sedative or cardiovascular effects. This patent also concerns a procedure to prepare bilastine and the use of this preparation to treat allergic reactions in mammals but it does not include or suggest the possible existence of polymorphic forms of this compound. To prepare pharmaceutical preparations containing bilastine for their administration in mammals and especially in man, in accordance with international health authority specifications, bilastine must be manufactured in the most stable crystalline form possible, especially in a form that has constant physical properties.
- We have found that bilastine can exist in three different crystalline polymorphic forms, each with different physical properties.
- The invention refers to
crystalline form 1 of bilastine, characterised by X-ray crystallographic analysis, with approximate crystal parameters as follows: -
Crystallographic system Monoclinic Spatial group P2 (1)/c Crystal size 0.56 × 0.45 × 0.24 mm Cell dimension a = 23.38 (5) A angstrom α = 90° b = 8.829 (17) A β = 90° c = 12.59 (2) A γ = 90° Volume 2600 A3 Z, calculated density 4, 1.184 mg/m3 - The
crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide tablet that has the following characteristic absorption bands, expressed in reciprocal centimetres: - 3430 (s)*; 3057 (w)*; 2970 (s); 2929 (s); 2883 (m)*; 2857 (m); 2797 (w); 1667 (m); 1614 (m); 1567 (w); 1509 (s); 1481 (m); 1459 (vs)*; 1431 (m); 1378 (w); 1346 (m); 1326 (m); 1288 (w); 1254 (m); 1199 (w); 1157 (w); 1121 (vs); 1045 (w); 1020 (w); 1010 (w); 991 (w); 973 (w); 945 (w); 829 (w); 742 (s); 723 (w); 630 (w), * where (w)=weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity.
FIG. 1 represents the infrared spectrum of thecrystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer. -
FIG. 1 shows a typical infrared absorption spectrum in potassium bromide ofcrystalline form 1. (Vertical axis: Transmission (%); Horizontal axis: Wavenumber (cm−1)). -
FIG. 2 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 2. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm−1)). -
FIG. 3 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 3. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm−1)). - We have found that bilastine can exist in three clearly different polymorphic forms called
crystalline form 1, crystalline form 2 and crystalline form 3. - The procedure described in U.S. Pat. No. 5,877,187 generates a mixture of crystalline forms 2 and 3. We have discovered experimental conditions and specific solvents to produce clearly different polymorphic forms of bilastin. The
crystalline form 1 of pure bilastine is prepared according to the procedures of this invention. Thecrystalline forms 1 and 2 are stable. - Crystalline form 3 is not very stable and is difficult to obtain in the pure form. Both crystalline form 2 and crystalline form 3 are converted into
crystalline form 1 by the procedures of this invention. -
Crystalline form 1 of bilastine has a melting point of 200.3° C. Crystalline form 2 has a melting point of 205.2° C. Crystalline form 3 has a melting point of 197.0° C. - The
crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres: - 3430 (s)*; 3057 (w)*; 2970 (s); 2929 (s); 2883 (m)*; 2857 (m); 2797 (w); 1667 (m); 1614 (m); 1567 (w); 1509 (s); 1481 (m); 1459 (vs)*; 1431 (m);1378 (w); 1346 (m); 1326 (m); 1288 (w); 1254 (m); 1199 (w); 1157 (w); 1121 (vs); 1045 (w); 1020 (w); 1010 (w); 991 (w); 973 (w); 945 (w); 829 (w); 742 (s); 723 (w); 630 (w), * where (w)=weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity.
FIG. 1 represents the infrared spectrum of thecrystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer. The crystalline form 2 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres: - 3429 (s)*; 3053 (w)*; 2970 (s)*; 2932 (s); 2868 (s); 2804 (w); 1699 (m); 1614 (m)*; 1567 (m); 1508 (s); 1461 (vs)*; 1381 (m); 1351 (s); 1331 (m); 1255 (m); 1201 (w); 1156 (m); 1121 (vs); 1048 (w); 995 (w); 823 (w); 767 (w); 744 (s); 724 (w); 630 (w), * where (w) =weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity.
FIG. 2 represents the infrared spectrum of the crystalline form 2 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer. - The crystalline form 3 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
- 3430 (s)*; 3053 (w)*; 2970 (s); 2932 (s); 2868 (s); 2804 (w); 1921 (w); 1708 (m)*; 1614 (m); 1568 (m); 1508 (s); 1461 (vs)*; 1380 (m); 1351 (m); 1330 (m); 1271 (m); 1255 (m); 1201 (w); 1156 (m); 1121 (vs); 1048 (w); 995 (w); 823 (m); 767 (w); 744 (s); 724 (w); 630 (w), * where (w) =weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity.
FIG. 3 represents the infrared spectrum of the crystalline 3 of the bilastine in a potassium bromide tablet recorded in Perkin Elmer Spectrum One FTIR spectrophotometer. - We have discovered that, under selected experimental conditions, the mixture of the crystalline forms 2 and 3, obtained according to U.S. Pat. No. 5,877,187, is surprisingly transformed into
crystalline form 1. We have also discovered thatcrystalline form 1 of bilastine is very stable and is not transformed into any of the other polymorphs 2 and 3. Similarly, in the same experimental conditions, the pure crystalline form 2 of bilastine is surprisingly transformed into the purecrystalline form 1. Crystalline form 3, which is the most unstable, undergoes the same transformation under the same conditions. -
Crystalline form 1 of bilastine is a very stable polymorph at room temperature and is, therefore, very useful as an active ingredient of a pharmaceutical preparation.Crystalline form 1 is also stable when stored at temperatures above room temperature. - The
crystalline form 1 of bilastine is characterised by the following data of its X-ray crystallographic analysis as a monocrystal, with crystal parameters of approximately the following values: -
Crystallograph system Monoclinic Spatial group P2 (1)/c Crystal size 0.56 × 0.45 × 0.24 mm Cell dimension a = 23.38 (5) A angstrom α = 90° b = 8.829 (17) A β = 90° c = 12.59 (2) A γ = 90° Volume 2600 A3 Z, calculated density 4, 1.184 mg/m3 - During the development of
crystalline form 1 of bilastine for pharmaceutical preparations, elaborated according to correct manufacturing procedures, we have discovered that crystallization of bilastine (prepared according to the description given in U.S. Pat. No. 5,877,187) from isopropylic alcohol and n-butanol, leads to generation of thepolymorphic form 1 of bilastine with a high yield. Crystallisation from acetone, dimethylsulfoxide, dimethylformamide, acetonitrile and tetrahydrofurane or its mixtures thereof also lead to generation ofcrystalline form 1, although with lower yields. It is, therefore, preferable to use the former solvents. - The infrared spectrum of
crystalline form 1 of bilastine in potassium bromide is characterised by the following bands, absent from polymorphs 2 and 3: - Wavenumber (cm−1)
- 3057
- 2929
- 2883
- 2857
- 2797
- 1667
- 1481
- 1431
- 1346
- 1326
- 1288
- 973
- 945
- 829
-
FIG. 1 shows the complete infrared spectrum ofcrystalline form 1 of bilastine in potassium bromide, recorded with Perkin Elmer Spectrum One spectrophotometer. - Pharmaceutical Preparations
- Pharmaceutical preparations of this invention can contain, as well as an effective quantity of
crystalline form 1 of bilastine as an active ingredient as an antiallergic or antihistaminic agent, several pharmaceutically acceptable excipients. The solid pharmaceutical preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid excipient can be one of several substances that act as diluents, aromatising agents, agglutinants or disintegrating agents and an encapsulation material. The powders and tablets preferentially contain from approximately 5 to approximately 20 per cent of the active ingredient. Appropriate solid excipients are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, waxes with low melting point, cocoa butter and similar products. The term “preparations” includes the formulation of the active ingredient with an excipient for encapsulation to produce a capsule in which the active ingredient (with or without other excipients) is surrounded with the excipient by an encapsulation material. Tablets, powders, cachets and capsules can be used as suitable forms for oral administration. The active ingredient can also be incorporated into a chewing gum that can contain sweeteners, flavorings and colorings as appropriate. - To prepare suppositories, a compound with a low melting point, such as a mixture of fatty acid glycerides or cocoa butter, is melted and the active ingredient is mixed well and homogeneously dispersed in the mixture with agitation. The homogeneous melted mixture is placed in the appropriate moulds and left to cool until it solidifies.
- Liquid preparations comprise suspensions that can be made by mixing the finely divided active ingredient in water with suspension agents.
- Also, topical preparations are considered for nasal, ophthalmic and dermal use. Appropriate formulae for nasal administration can correspond to solutions or suspensions. Ophthalmic formulae can be suspensions and ointments. Dermal preparations can be suspensions, ointments and creams. Ointments usually contain lipophylic excipients such as mineral oil or vaseline.
- Similarly, a compound is being contemplated for transdermic use, consisting of a therapeutically effective amount of active ingredient incorporated into an excipient that corresponds to a liquid, a gel, a solid matrix or an adhesive patch sensitive to pressure, to be released via a transdermic administration system.
- The effective antiallergic or antihistaminic amount of
crystalline form 1 of bilastine for topical administration varies between 0.1 and 5% of the total weight of the pharmaceutical compound. The preferred amount ranges from 0.1 to 2% of the total weight of the pharmaceutical compound. - The effective antiallergic or antihistaminic amount of
crystalline form 1 of bilastine for oral administration varies from 1 to 50 mg/day, with preferably an amount corresponding to approximately 2 to 20 mg/day in a single or fractionated doses. -
Crystalline form 1 of bilastine has antihistaminic properties that have been demonstrated in experimental pharmacological models, such as preventing histamine-induced lethality in the guinea-pig and antagonism against cutaneous capillary permeability induced by histamine in the rat. - The following examples illustrate but do not limit the scope of the present invention.
- Preparation of
crystalline form 1 of bilastine. Dissolve bilastine (see the U.S. Pat. No. 5,877,187) in isopropylic alcohol heated to reflux for approximately 15-20 minutes under nitrogen while stirring. Cool the solution to 50° C. over 6 hours and stop stirring. Let the solution cool to room temperature and stir again for three hours, filter and wash with cold isopropylic alcohol. Dry the solid residue in a vacuum oven at 35-40° C. to constant weight. - Preparation of
crystalline form 1 of bilastine. - Heat a suspension of bilastine (see U.S. Pat. No. 5,877,187) in n-butanol and reflux for 3 hours under nitrogen while stirring. Leave the solution to cool while stirring, filter off the solid residue and dry it in a vacuum oven at 35-40° C. to constant weight.
- Preparation of
crystalline form 1 of bilastine. - Treat a mixture of polymorphs 2 and 3 of bilastine for several hours with hot acetone. Let the mixture cool to room temperature and filter off the solid residue. Dry it to constant weight.
- Preparation of
crystalline form 1 of bilastine. - Dissolve crystalline form 3 of bilastine in isopropylic alcohol heated to reflux and stir for approximately 15-20 minutes under nitrogen. Let the solution reach room temperature constantly stirring, filtering and washing with cold isopropanol. Dry the solid in a vacuum oven at 35-40° C. to constant weight.
- Preparation of
crystalline form 1 of bilastine. - Dissolve crystalline form 2 of bilastine in n-butanol heated to reflux while stirring for approximately 3 hours. Let the solution reach room temperature while stirring, filtering and draining. Dry the solid in a vacuum oven at 35-40° C. to constant weight.
Claims (8)
1. A liquid antihistaminic pharmaceutical composition comprising the crystalline form 1 of bilastine as the active ingredient together with at least one excipient, said crystalline form 1 of bilastine having, upon X-ray crystallography analysis, crystal parameters of substantially the following:
an infrared spectrum in potassium bromide with the following bands:
Wavenumber (cm−1)
3057
2929
2883
2857
2797
1666
1481
1431
1346
1326
1288
1020
973
945
829
and an infrared spectrum in potassium bromide which is substantially identical to that shown in FIG. 1 .
2. A liquid antihistaminic pharmaceutical composition according to claim 1 , wherein said composition is a suspension.
3. A liquid antihistaminic pharmaceutical composition according to claim 1 , wherein said composition is an emulsion.
4. A liquid antihistaminic pharmaceutical composition according to claim 1 , wherein said composition is a lotion.
5. A liquid antihistaminic pharmaceutical composition according to claim 1 , wherein said composition is a cream.
6. A liquid antihistaminic pharmaceutical composition according to claim 1 , wherein said composition is an ointment.
7. A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient a liquid pharmaceutical composition according to claim 1 .
8. A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient an effective amount of crystalline form 1 of bilastine in a liquid pharmaceutical composition according to claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/561,148 US20100004285A1 (en) | 2002-04-19 | 2009-09-16 | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/511,822 US7612095B2 (en) | 2002-04-19 | 2002-04-19 | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid |
ESPCT/ES02/00194 | 2002-04-19 | ||
PCT/ES2002/000194 WO2003089425A1 (en) | 2002-04-19 | 2002-04-19 | Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic |
US12/561,148 US20100004285A1 (en) | 2002-04-19 | 2009-09-16 | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/511,822 Continuation US7612095B2 (en) | 2002-04-19 | 2002-04-19 | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100004285A1 true US20100004285A1 (en) | 2010-01-07 |
Family
ID=29225789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/511,822 Active 2024-08-09 US7612095B2 (en) | 2002-04-19 | 2002-04-19 | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid |
US12/561,148 Abandoned US20100004285A1 (en) | 2002-04-19 | 2009-09-16 | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/511,822 Active 2024-08-09 US7612095B2 (en) | 2002-04-19 | 2002-04-19 | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid |
Country Status (31)
Country | Link |
---|---|
US (2) | US7612095B2 (en) |
EP (1) | EP1505066B1 (en) |
JP (1) | JP5142448B2 (en) |
KR (1) | KR100673140B1 (en) |
CN (1) | CN1290843C (en) |
AR (1) | AR039423A1 (en) |
AT (1) | ATE347550T1 (en) |
AU (1) | AU2002255017B2 (en) |
BG (1) | BG66302B1 (en) |
BR (1) | BRPI0215703B8 (en) |
CA (1) | CA2484460C (en) |
CY (2) | CY1107564T1 (en) |
CZ (1) | CZ305162B6 (en) |
DE (1) | DE60216641T2 (en) |
DK (1) | DK1505066T3 (en) |
ES (1) | ES2278018T3 (en) |
HK (1) | HK1072772A1 (en) |
HR (1) | HRP20041048B1 (en) |
HU (1) | HU230032B1 (en) |
IL (1) | IL164645A (en) |
MX (1) | MXPA04010313A (en) |
NO (1) | NO329327B1 (en) |
NZ (1) | NZ536551A (en) |
PA (1) | PA8571201A1 (en) |
PE (1) | PE20040086A1 (en) |
PT (1) | PT1505066E (en) |
SI (1) | SI1505066T1 (en) |
SK (1) | SK288052B6 (en) |
UA (1) | UA76866C2 (en) |
UY (1) | UY27762A1 (en) |
WO (1) | WO2003089425A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140194111A1 (en) * | 2011-06-30 | 2014-07-10 | Panasonic Corporation | Communication system, user terminal, and communication device |
WO2017191651A1 (en) * | 2016-05-05 | 2017-11-09 | Msn Laboratories Private Limited, R & D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010013472A (en) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID |
CN102675101B (en) * | 2012-05-16 | 2014-01-29 | 王蕾 | Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine |
CZ307500B6 (en) | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | A method of the preparation of a 2-methyl-2'-phenylpropionic acid derivative employing novel intermediates |
CN103214454A (en) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | Bilastine crystal and preparation method thereof |
WO2014188453A2 (en) * | 2013-05-24 | 2014-11-27 | Msn Laboratories Private Limited | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid |
CN103356616A (en) * | 2013-06-29 | 2013-10-23 | 北京万全德众医药生物技术有限公司 | Bilastine-containing pharmaceutical composition and preparation method thereof |
CN104447682A (en) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | Bilastine compound |
CN104398481A (en) * | 2014-10-29 | 2015-03-11 | 万全万特制药江苏有限公司 | Bilastine orally disintegrating tablet and preparing method thereof |
SI3327012T1 (en) * | 2015-07-24 | 2021-10-29 | Urquima Sa | Crystalline forms of bilastine and preparation methods thereof |
EP3170817A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
EP3170816A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
WO2017167949A1 (en) | 2016-04-01 | 2017-10-05 | Krka, D.D., Novo Mesto | Crystalline forms of bilastine |
EP3453384B1 (en) | 2017-09-07 | 2020-05-27 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine |
EP3470062B1 (en) | 2017-12-18 | 2020-10-28 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate |
PL3641735T3 (en) | 2017-12-18 | 2021-09-06 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler |
CA3088740A1 (en) | 2018-01-18 | 2019-07-25 | Faes Farma, S.A. | Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent |
WO2022135863A1 (en) | 2020-12-23 | 2022-06-30 | Biohorm, S.L. | A non-micronized bilastine composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877187A (en) * | 1996-06-04 | 1999-03-02 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
TR200103851T2 (en) * | 1999-04-16 | 2002-04-22 | Dr. Reddy' S Research Foundation | New polymorphic forms of an antidiabetic agent, the process for their preparation, and pharmaceutical compositions thereof |
US6806280B1 (en) * | 1999-04-23 | 2004-10-19 | Smithkline Beecham P.L.C. | Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt |
-
2002
- 2002-04-19 EP EP02724323A patent/EP1505066B1/en not_active Expired - Lifetime
- 2002-04-19 MX MXPA04010313A patent/MXPA04010313A/en active IP Right Grant
- 2002-04-19 JP JP2003586146A patent/JP5142448B2/en not_active Expired - Lifetime
- 2002-04-19 DK DK02724323T patent/DK1505066T3/en active
- 2002-04-19 UA UA20041109444A patent/UA76866C2/en unknown
- 2002-04-19 KR KR1020047016676A patent/KR100673140B1/en active IP Right Grant
- 2002-04-19 SK SK5020-2004A patent/SK288052B6/en not_active IP Right Cessation
- 2002-04-19 CA CA002484460A patent/CA2484460C/en not_active Expired - Fee Related
- 2002-04-19 ES ES02724323T patent/ES2278018T3/en not_active Expired - Lifetime
- 2002-04-19 US US10/511,822 patent/US7612095B2/en active Active
- 2002-04-19 DE DE60216641T patent/DE60216641T2/en not_active Expired - Lifetime
- 2002-04-19 CN CNB028289870A patent/CN1290843C/en not_active Ceased
- 2002-04-19 SI SI200230485T patent/SI1505066T1/en unknown
- 2002-04-19 AU AU2002255017A patent/AU2002255017B2/en not_active Expired
- 2002-04-19 WO PCT/ES2002/000194 patent/WO2003089425A1/en active IP Right Grant
- 2002-04-19 PT PT02724323T patent/PT1505066E/en unknown
- 2002-04-19 AT AT02724323T patent/ATE347550T1/en active
- 2002-04-19 NZ NZ536551A patent/NZ536551A/en not_active IP Right Cessation
- 2002-04-19 BR BRPI0215703A patent/BRPI0215703B8/en active IP Right Grant
- 2002-04-19 HU HU0500241A patent/HU230032B1/en unknown
- 2002-04-19 CZ CZ2004-1122A patent/CZ305162B6/en not_active IP Right Cessation
-
2003
- 2003-04-14 PE PE2003000376A patent/PE20040086A1/en active IP Right Grant
- 2003-04-14 UY UY27762A patent/UY27762A1/en not_active Application Discontinuation
- 2003-04-15 AR ARP030101325A patent/AR039423A1/en not_active Application Discontinuation
- 2003-04-16 PA PA20038571201A patent/PA8571201A1/en unknown
-
2004
- 2004-10-17 IL IL164645A patent/IL164645A/en active IP Right Grant
- 2004-11-09 HR HRP20041048AA patent/HRP20041048B1/en not_active IP Right Cessation
- 2004-11-17 NO NO20044999A patent/NO329327B1/en not_active IP Right Cessation
- 2004-11-18 BG BG108941A patent/BG66302B1/en unknown
-
2005
- 2005-07-27 HK HK05106418A patent/HK1072772A1/en not_active IP Right Cessation
-
2007
- 2007-02-23 CY CY20071100259T patent/CY1107564T1/en unknown
-
2009
- 2009-09-16 US US12/561,148 patent/US20100004285A1/en not_active Abandoned
-
2013
- 2013-04-24 CY CY2013015C patent/CY2013015I2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877187A (en) * | 1996-06-04 | 1999-03-02 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) | Benzimidazole derivatives with antihistaminic activity |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140194111A1 (en) * | 2011-06-30 | 2014-07-10 | Panasonic Corporation | Communication system, user terminal, and communication device |
WO2017191651A1 (en) * | 2016-05-05 | 2017-11-09 | Msn Laboratories Private Limited, R & D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100004285A1 (en) | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID | |
EP1021439B1 (en) | Crystalline antifungal polymorph | |
US6958337B2 (en) | Crystalline antifungal polymorph | |
SK286197B6 (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino) ethoxy]benzyl]- thiazolidine-2,4-dione maleic acid salt | |
KR100419404B1 (en) | Vitreous form of known bradykinin antagonist | |
US7335380B2 (en) | Amlodipine free base | |
RU2288917C2 (en) | POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-PIPERIDINYL]ETHYL]-α,α-DIMETHYLBENZENEACETIC ACID, METHOD FOR ITS PREPARING, PHARMACEUTICAL PREPARATION BASED ON THEREOF AND ITS USING | |
US5106859A (en) | Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient | |
JP2010013472A (en) | POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID | |
PL205568B1 (en) | Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |